Vascular dementia: galantamine (Reminyl®) as an emerging therapeutic option
G. W. Small,
G. W. Small
UCLA Neuropsychiatric Institute, Los Angeles, CA, USA
Search for more papers by this authorG. W. Small,
G. W. Small
UCLA Neuropsychiatric Institute, Los Angeles, CA, USA
Search for more papers by this authorGary W. Small, M.D., Parlow-Solomon Professor on Aging, Professor of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, 88–201, 760 Westwood Plaza, Los Angeles, CA 90024, USA
Tel.: +1 310 825 0291
Fax: +1 310 825 3910
e-mail: [email protected]
No abstract is available for this article.
References
- 1 Aguero-Torres H, Winblad B, Fratiglioni L. Epidemiology of vascular dementia: some results despite research limitations. Alzheimer Dis Assoc Disord 1999; 13(Suppl. 3): S15–20.
- 2 Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473–80.
- 3 Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13(Suppl. 3): S115–23.
- 4 Rockwood K, Bowler J, Erkinjuntti T, Hachinski V, Wallin A. Subtypes of vascular dementia. Alzheimer Dis Assoc Disord 1999; 13(Suppl. 3): S59–65.
- 5 Chui H, Gonthier R. Natural history of vascular dementia. Alzheimer Dis Assoc Disord 1999; 13(Suppl. 3): S124–30.
- 6 Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994; 5: 163–7.
- 7 Román GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN Intenational Workshop. Neurology 1993; 43: 250–60.
- 8 Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103: 1211–20.
- 9 Wallin A, Blennow K, Gottfries CG. Neurochemical abnormalities in vascular dementia. Dementia 1989; 1: 120–30.
- 10 Winblad B, Brodaty H, Gauthier S et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16: 653–66.
- 11 Albuquerque EX, Santos MD, Alkondon M, Pereira EFR, Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15(Suppl. 1): S19–25.
- 12 Gattu M, Pauly JR, Boss KL, Summers JB, Buccafusco JJ. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors. I. Brain Res 1997; 771: 89–103.
- 13 Gitelman DR, Prohovnik I. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging 1992; 13: 313–18.
- 14 Saito H, Togashi H, Yoshioka M, Nakamura N, Minami M, Parvez H. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995; 22(Suppl. 1): S257–9.
- 15 Terry AV Jr, Hernandez CM, Buccafusco JJ, Gattu M. Deficits in spatial learning and nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats. Neuroscience 2000; 101: 357–68.
- 16 Togashi H, Matsumoto M, Yoshioka M, Hirokami M, Minami M, Saito H. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117–20.
- 17 Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261–8.
- 18 Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76.
- 19 Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445–9.
